The subscription period for the Rights Issue expired on July 22, 2025 and the final summary shows that 19,666,132 shares, corresponding to approximately 89 percent, were subscribed for through subscription rights. In addition, 27,171,095 additional shares were subscribed for without subscription rights. The total subscription level amounted to approximately 212 per cent of the size of the Rights Issue. The Board of Directors of the Company has also decided to exercise the option to expand the Rights Issue with the over-allotment option as disclosed in the information material, which means that AlzeCure issues 22,073,800 new shares in the Rights Issue and 4,545,455 additional new shares after exercising the over-allotment option, a total of 26,619,255 new shares. AlzeCure will thus receive approximately 58.5 MSEK before issue costs. No remuneration has been given to any participants in the issue.
Related information documents
Press releases
-
AlzeCure’s rights issue oversubscribed and the company resolves on a directed share issue under the framework of an overallotment option
July 24, 2025
-
AlzeCure’s rights issue oversubscribed according to preliminary results
July 24, 2025
-
AlzeCure’s rights issue oversubscribed according to preliminary results
July 23, 2025
-
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue
July 16, 2025
-
AlzeCure Pharma publishes amended Information document regarding rights issue
July 7, 2025
-
AlzeCure Pharma publishes Information document regarding rights issue
July 4, 2025
-
AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the upcoming Rights Issue
June 17, 2025
